A Liquid Biopsy Approach for Early Diagnosis of Parkinson’s Disease

Brain diseases like Parkinson’s start to develop long before symptoms show up, but diagnosing these disorders early is very difficult. Being able to detect them in these early stages could slow or even stop the disease, but current diagnostic methods, like brain tissue analysis, can only be done after death. To solve this, scientists are working on “liquid biopsies” – a new approach that analyzes blood or other body fluids to find signs of disease without any invasive procedures. They’re focusing on tiny particles in the blood called extracellular vesicles (EVs). These particles are released by cells and carry molecules specific to certain tissues, like the brain. This means EVs could contain markers that signal early brain disease. One big challenge has been determining whether these markers are actually inside the EVs or just stuck to their surface. Dr. David Walt’s team at Harvard solved this by adding a step to remove surface-bound proteins, allowing them to analyze the true contents of EVs. Using this method, they detected a protein called α-synuclein, which is linked to Parkinson’s, specifically within the EVs rather than floating freely in blood plasma. Their technique also identifies a modified form of α-synuclein, which builds up as Parkinson’s progresses. In tests with blood samples from Parkinson’s patients, they found that this modified protein was more concentrated in the EVs compared to healthy individuals. This suggests EVs may help preserve early signs of the disease. This new method could one day allow doctors to diagnose brain diseases like Parkinson’s early on, simply through a blood test, providing a glimpse into brain health without needing invasive procedures.